IHMT-PI3Kδ-372 NEW
| Price | $46 | $113 | $178 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: IHMT-PI3Kδ-372 | CAS No.: 2429889-62-1 |
| Purity: 99.54% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | IHMT-PI3Kδ-372 |
| Description | IHMT-PI3Kδ-372 is a selective inhibitor of PI3Kδ with an IC50 of 14 nM and can be used in studies about chronic obstructive pulmonary disease. |
| In vitro | In Raji cells, IHMT-PI3Kδ-372 (0.03-3 μM) inhibits PI3Kδ-mediated AKT T308 phosphorylation (EC50 = 67 nM).IHMT-PI3Kδ-372 moderately inhibits CYP2C9 (IC50 = 2.7 μM) and no apparently inhibits CYP1A2, CYP2B6, CYP2C19, and CYP3A4 (IC50s > 10 μM)[1]. |
| In vivo | IHMT-PI3Kδ-372 (1-5 mg/kg; inhalation) improves lung function and reduced the inflammatory patterns characteristic of COPD with better forced expiratory volume in FEV1, FVC, and PEF. IHMT-PI3Kδ-372 dose-dependently decreases the inflammatory cell and reduces the abnormally high level of leukocytes including the alveolar macrophages, neutrophils, and lymphocytes. In rats, IHMT-PI3Kδ-372 (5 mg/kg; inhalation) displays a half-life of 2.3 h, low exposure of 66 ng/mL, and high clearance of 348.5 mL/min/kg in plasma and high exposure of 5599 ng/g (6 h after inhalation) in lung tissue[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 37.8 mg/mL (75.1 mM), Sonication is recommended. |
| Keywords | IHMT-PI3Kdelta-372 | IHMTPI3Kδ372 | IHMT-PI-3Kδ-372 | IHMT PI3Kδ 372 |
| Inhibitors Related | Myricetin | Erucic acid | Sapanisertib | (2S,3R,4S)-4-Hydroxyisoleucine | Duvelisib (R enantiomer) hydrochloride | Isoprenaline hydrochloride | Quercetin | GDC0084 | Quercetin Dihydrate | Apilimod | LY294002 | Idelalisib |
| Related Compound Libraries | Bioactive Compound Library | Antidepressant Compound Library | Kinase Inhibitor Library | Anti-Ovarian Cancer Compound Library | Anti-Cancer Metabolism Compound Library | Anti-Breast Cancer Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $3520.00/100mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-23 | |
| $30.00/5mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
| $9.90/10g |
VIP4Y
|
Wuhan Biocar Pharmacy CO.,Ltd.
|
2022-10-21 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY